Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited ( (HK:2181) ) has provided an update.
Mabpharm Limited has announced that its board of directors will meet on August 28, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will determine the company’s financial performance and could impact its market positioning and stakeholder interests.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and production of biopharmaceutical products.
Average Trading Volume: 530,203
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.72B
For a thorough assessment of 2181 stock, go to TipRanks’ Stock Analysis page.